DUR 928

Drug Profile

DUR 928

Alternative Names: DUR928; DV-928

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator DURECT Corporation
  • Class Small molecules
  • Mechanism of Action Inflammation mediator modulators; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute kidney injury; Fatty liver; Non-alcoholic steatohepatitis; Psoriasis
  • Preclinical Liver disorders; Stroke

Most Recent Events

  • 24 Apr 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase Ib trial in Non-alcoholoc steatohepatitis presented at the 52nd annual meeting of the European Association for the Study of the Liver (EASL-2017)
  • 14 Mar 2017 DURECT plans a phase II trial for Primary sclerosing cholangitis (PO)
  • 14 Mar 2017 DURECT plans a proof-of-concept, topical application microplaque clinical trial for Psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top